Compare Ecolab Inc. (ECL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs TG Therapeutics Inc — how do they compare? Ecolab Inc. trades at $281.42 (market cap $78.97B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Ecolab Inc. is far larger — about 9.7× TG Therapeutics Inc's market cap, and Ecolab Inc. pays a 1.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and TG Therapeutics Inc for 16 Days on average.
| ECL | TGTX | |
|---|---|---|
Market Cap | $78.97B | $8.16B |
Volume | 974,947 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $59.06 |
52-Week Low | $245.73 | $26.94 |
Typical Hold Time | 90 Days | 16 Days |
Enterprise Value | $87.75B | $8.37B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $281.83, up 1.34% today, with strong analyst support (78% buy ratings) and a $326.38 consensus price target. The stock shows bullish technical momentum above key support at $279, while fundamentals reveal steady revenue growth to $16.08B in 2025 and robust profitability with 12.57% net margins. Recent Q2 earnings beat expectations, and the company maintains dividend aristocrat status with consistent payout increases.
Outlook remains positive given ECL's essential service contracts, digital segment growth, and high institutional ownership. Key risks include rising debt from the $4.75B CoolIT acquisition and cost inflation pressures. The stock offers a compelling growth-and-income profile for investors seeking exposure to defensive industrial services with recurring revenue streams.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
